Apixaban Hold Duration for PEG Tube Placement
For patients with normal renal function, hold apixaban (Eliquis) for at least 48 hours before PEG tube placement; for patients with creatinine clearance 30-50 mL/min, extend the hold to 72 hours, and for creatinine clearance <30 mL/min, hold for at least 72 hours or longer based on clinical judgment. 1
Procedural Risk Classification
- PEG tube placement is classified as a high-risk bleeding procedure by the British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE). 1
- This classification mandates specific anticoagulation management protocols distinct from low-risk diagnostic procedures. 1
Standard Hold Duration Based on Renal Function
Normal Renal Function (CrCl ≥50 mL/min)
- Hold apixaban for at least 48 hours (take the last dose ≥48 hours before the procedure). 1
- The FDA label for apixaban recommends discontinuation at least 48 hours prior to elective surgery or invasive procedures with moderate or high bleeding risk. 2
Moderate Renal Impairment (CrCl 30-50 mL/min)
- Hold apixaban for 72 hours before the procedure. 1
- This extended duration accounts for reduced drug clearance in renal impairment. 1
Severe Renal Impairment (CrCl <30 mL/min)
- Hold apixaban for at least 72 hours, potentially longer based on clinical assessment. 1
- Consider consulting a hematologist for patients with rapidly deteriorating renal function. 1
- Apixaban-calibrated anti-Xa levels may guide decision-making in this population, as drug half-life can be significantly prolonged. 3
Clinical Context and Nuances
Evidence Quality Considerations
- The BSG/ESGE guidelines acknowledge this recommendation is based on very low quality evidence but maintain a strong recommendation given the pharmacokinetic properties of DOACs and bleeding risk. 1
- Real-world data from the ADIOS study demonstrated that 94% of patients achieved clinically insignificant apixaban concentrations (≤30 ng/mL) when the drug was held for a median of 76 hours. 4
Thrombotic Risk Assessment
- Evaluate the patient's thrombotic risk using established criteria (mechanical heart valves, recent VTE <3 months, recent coronary stents, atrial fibrillation with mitral stenosis). 1
- For patients at high thrombotic risk, coordinate with cardiology or hematology regarding bridging strategies, though bridging is generally not recommended for DOACs due to similar pharmacokinetic properties to LMWH. 5, 6
- For patients at low thrombotic risk, no bridging anticoagulation is required during the 48-72 hour interruption. 5
Resumption of Apixaban Post-Procedure
- Restart apixaban 48-72 hours after PEG placement once adequate hemostasis is confirmed. 1, 7, 6
- The timing should be discussed with the performing endoscopist and favor the longer interval (72 hours) to minimize post-procedural bleeding risk. 6
- The FDA label states apixaban should be restarted "as soon as adequate hemostasis has been established." 2
Critical Pitfalls to Avoid
- Do not continue apixaban through the procedure—PEG placement carries significant bleeding risk that outweighs the brief thrombotic risk during a 48-72 hour hold. 1, 6
- Do not use a uniform 48-hour hold for all patients—adjust based on renal function, as patients with CrCl 30-50 mL/min require 72 hours and those with CrCl <30 mL/min may need even longer. 1
- Do not restart anticoagulation too early—verify hemostasis before resuming apixaban, as premature resumption increases bleeding complications. 7, 6
- Do not routinely bridge with LMWH—bridging increases bleeding risk without reducing thrombotic events in most patients and should be reserved only for truly high-risk cases (mechanical mitral valve, recent drug-eluting stent <12 months). 5, 6
- Monitor renal function closely—fluctuations in kidney function are common in hospitalized patients and may necessitate dosage adjustments or extended hold periods. 8, 3